Literature DB >> 31127560

Metabolomics Analyses from Tissues in Parkinson's Disease.

Fatema Bhinderwala1, Shulei Lei1, Jade Woods1, Jordan Rose2,3, Darrell D Marshall1, Eli Riekeberg1, Aline De Lima Leite1,4, Martha Morton1,4, Eric D Dodds1,4, Rodrigo Franco5,6, Robert Powers7,8,9.   

Abstract

Metabolomics has been successfully applied to study neurological and neurodegenerative disorders including Parkinson's disease for (1) the identification of potential biomarkers of onset and disease progression; (2) the identification of novel mechanisms of disease progression; and (3) the assessment of treatment prognosis and outcome. Reproducible and efficient extraction of metabolites is imperative to the success of any metabolomics investigation. Unlike other omics techniques, the composition of the metabolome can be negatively impacted by the preparation, processing, and handling of these samples. The proper choice of data collection, preprocessing, and processing protocols is similarly important to the design of an effective metabolomics experiment. Likewise, the correct application of univariate and multivariate statistical methods is essential for providing biologically relevant insights. In this chapter, we have outlined a detailed metabolomics workflow that addresses all of these issues. A step-by-step protocol from the preparation of neuronal cells and metabolomic tissue samples to their metabolic analyses using nuclear magnetic resonance, mass spectrometry, and chemometrics is presented.

Entities:  

Keywords:  Chemometrics; Mass spectrometry; Metabolomics; NMR; Neurodegeneration; Parkinson’s disease

Year:  2019        PMID: 31127560      PMCID: PMC6625357          DOI: 10.1007/978-1-4939-9488-5_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  51 in total

Review 1.  Metabolomics of neurodegenerative diseases.

Authors:  Alejandro Botas; Hannah Moore Campbell; Xu Han; Mirjana Maletic-Savatic
Journal:  Int Rev Neurobiol       Date:  2015-07-29       Impact factor: 3.230

2.  Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.

Authors:  Jesper F Havelund; Andreas D Andersen; Michael Binzer; Morten Blaabjerg; Niels H H Heegaard; Egon Stenager; Nils J Faergeman; Jan Bert Gramsbergen
Journal:  J Neurochem       Date:  2017-07-11       Impact factor: 5.372

3.  Multiple significance tests: the Bonferroni method.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1995-01-21

Review 4.  Application of NMR metabolomics to search for human disease biomarkers.

Authors:  Teklab Gebregiworgis; Robert Powers
Journal:  Comb Chem High Throughput Screen       Date:  2012-09       Impact factor: 1.339

5.  3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.

Authors:  Peter A Lewitt; Jia Li; Mei Lu; Thomas G Beach; Charles H Adler; Lining Guo
Journal:  Mov Disord       Date:  2013-07-19       Impact factor: 10.338

6.  NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm.

Authors:  Tim De Meyer; Davy Sinnaeve; Bjorn Van Gasse; Elena Tsiporkova; Ernst R Rietzschel; Marc L De Buyzere; Thierry C Gillebert; Sofie Bekaert; José C Martins; Wim Van Criekinge
Journal:  Anal Chem       Date:  2008-04-18       Impact factor: 6.986

7.  Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility.

Authors:  Stewart G Gardner; Darrell D Marshall; Robert S Daum; Robert Powers; Greg A Somerville
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 8.  New Developments in Genetic rat models of Parkinson's Disease.

Authors:  Rose B Creed; Matthew S Goldberg
Journal:  Mov Disord       Date:  2018-02-08       Impact factor: 10.338

Review 9.  Parkinson's disease: animal models and dopaminergic cell vulnerability.

Authors:  Javier Blesa; Serge Przedborski
Journal:  Front Neuroanat       Date:  2014-12-15       Impact factor: 3.856

10.  Metabolomics and in-silico analysis reveal critical energy deregulations in animal models of Parkinson's disease.

Authors:  Pierre O Poliquin; Jingkui Chen; Mathieu Cloutier; Louis-Éric Trudeau; Mario Jolicoeur
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more
  4 in total

1.  Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome.

Authors:  Md Shadman Ridwan Abid; Haowen Qiu; Bridget A Tripp; Aline de Lima Leite; Heidi E Roth; Jiri Adamec; Robert Powers; James W Checco
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

2.  Metabolic Alterations in a Drosophila Model of Parkinson's Disease Based on DJ-1 Deficiency.

Authors:  Cristina Solana-Manrique; Francisco José Sanz; Isabel Torregrosa; Martina Palomino-Schätzlein; Carolina Hernández-Oliver; Antonio Pineda-Lucena; Nuria Paricio
Journal:  Cells       Date:  2022-01-20       Impact factor: 6.600

3.  Multi-Omics Integration in Mice With Parkinson's Disease and the Intervention Effect of Cyanidin-3-O-Glucoside.

Authors:  Wang Wang; Guoxue Zhu; Yuwen Wang; Wei Li; Shilin Yi; Kai Wang; Lu Fan; Juanjuan Tang; Ruini Chen
Journal:  Front Aging Neurosci       Date:  2022-04-29       Impact factor: 5.750

Review 4.  Quantitative NMR-Based Biomedical Metabolomics: Current Status and Applications.

Authors:  Alexandra A Crook; Robert Powers
Journal:  Molecules       Date:  2020-11-04       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.